Corrigendum to: “Discovery and optimization of tetrahydroacridine derivatives as a novel class of antibiotics against multidrug-resistant gram-positive pathogens by targeting type I signal peptidase and disrupting bacterial membrane” [Eur. J. Med. Chem. ISSN 0223–5234, (283, 2025, 117101]

IF 6 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-06-30 DOI:10.1016/j.ejmech.2025.117916

Xiaolin Lu , Jinhu Huang

引用次数: 0

查看原文本刊更多论文

对“四氢吖啶衍生物的发现和优化，作为一类新的抗生素，通过靶向I型信号肽酶和破坏细菌膜来对抗多重耐药的革兰氏阳性病原体”的更正[欧洲]。医学化学。Issn 0223-5234, （283, 2025, 117101）

没有抽象的

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.